If FCR may be the cure of choice, warning need to be taken in patients with NOTCH1 mutations, in whom rituximab appears to own tiny added benefit.59 Other genomic subgroups, such as patients with BIRC3 mutations look to derive little take advantage of CIT,111,112 but these success must be further more validated.CMD368 is a global bookmaker company,